<DOC>
	<DOCNO>NCT02362594</DOCNO>
	<brief_summary>This study ass whether post-resection adjuvant therapy pembrolizumab improve recurrence-free survival ( RFS ) compare placebo high-risk participant melanoma ( Stage IIIA [ &gt; 1 mm metastasis ] , IIIB IIIC ) . The study also assess whether pembrolizumab improve RFS versus placebo subgroup participant program cell death ligand 1 ( PD-L1 ) -positive tumor expression . Participants stratify stage disease region randomly assign receive either pembrolizumab placebo .</brief_summary>
	<brief_title>Study Pembrolizumab ( MK-3475 ) Versus Placebo After Complete Resection High-Risk Stage III Melanoma ( MK-3475-054/KEYNOTE-054 )</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<criteria>Inclusion criterion : Completely resect Stage III melanoma Tumor tissue available evaluation PDL1 expression Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Adequate organ function No prior therapy melanoma except surgery primary melanoma lesion ( previously treat interferon thick primary melanoma without evidence lymph node involvement eligible ) Female participant childbearing potential willing use adequate method birth control surgically sterile , abstain heterosexual activity course study 120 day last dose study medication Male participant agree use adequate method birth control start first dose study therapy 120 day last dose study medication Exclusion criterion : Mucosal ocular melanoma History pneumonitis require treatment steroid History interstitial lung disease History hematologic primary solid tumor malignancy , unless evidence disease 5 year Active autoimmune disease require systemic treatment past 2 year Active infection require therapy Unstable hyperthyroidism hypothyroidism Diagnosis immunodeficiency Systemic steroid therapy form immunosuppressive therapy within 7 day prior first dose study medication Known history human immunodeficiency virus ( HIV ) , active Hepatitis B C Treatment live vaccine within 30 day prior first dose study medication eligible Prior treatment anticytotoxic Tlymphocyteassociated protein 4 ( CTLA4 ) monoclonal antibody antiPD1 , PDL1 PDL2 agent , prior participation Merck pembrolizumab clinical trial Currently participate receive study therapy , participate study investigational agent receive study therapy use investigation device within 4 week first dose study medication Pregnant breastfeeding , expect conceive father child within project duration trial , start screen visit 120 day last dose study medication Patient immediate family member ( e.g. , spouse , parent/legal guardian , sibling child ) investigational site Sponsor staff directly involve trial without prospective Institutional Review Board approval ( chair designee ) give</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>PD1</keyword>
	<keyword>PDL1</keyword>
</DOC>